Evidence map›Paper›PMID 41562169›Full record

ArticleAnnals of Saudi medicine

Investigation of the susceptibility rates to ceftazidime-avibactam and colistin, clonal relationships, and clinical data of patients with carbapenem-resistant

Yüksel Akkaya, İrfan Aydın, Sebile Harmankaya, Mehmet Karakuş, Mehtap Aydin, Begüm Nalça Erdin, Ahmet Münir Yılmaz, Emine Hüdanur Büyükavcı, Zülal Așçı Toraman, İbrahim Halil Kılıç

Abstract read
In one paragraph

Article in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yüksel AkkayaFrom the Department of Microbiology, Faculty of Medicine, University of Health Sciences Hamidiye, Üsküdar, Istanbul, Türkiye.ORCID 0000-0003-1297-944X
İrfan AydınFrom the Pharmacy Services Department, Fenerbahçe University, Istanbul, Türkiye.
Sebile HarmankayaFrom the Medical Microbiology Laboratory, Ümraniye Training and Research Hospital, Istanbul, Türkiye.
Mehmet KarakuşFrom the Department of Microbiology, Faculty of Medicine, University of Health Sciences Hamidiye, Üsküdar, Istanbul, Türkiye.
Mehtap AydinFrom the Department of Infectious Diseases and Clinical Microbiology, Ümraniye Training and Research Hospital, Istanbul, Türkiye.
Begüm Nalça ErdinFrom the Medical Microbiology Laboratory, Ümraniye Training and Research Hospital, Istanbul, Türkiye.
Ahmet Münir YılmazFrom the Department of Emergency Medicine, Abdulkadir Yuksel State Hospital, Ministry of Health, Gaziantep, Türkiye.
Emine Hüdanur BüyükavcıFrom the Medical Microbiology Laboratory, Ümraniye Training and Research Hospital, Istanbul, Türkiye.
Zülal Așçı ToramanFrom the Department of Medical Microbiology, Faculty of Medicine, Firat University, Elazig, Türkiye.
İbrahim Halil KılıçFrom the Molecular Biology Department, Faculty of Arts and Sciences, Gaziantep University, Gaziantep, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increase in carbapenem-resistant

objectivesThe aim of this study was to investigate the susceptibility rates of CR-Kp isolates obtained from ICUs to ceftazidime-avibactam (CAZ-AVI) and colistin, carbapenem resistance genes, clonal relationships and clinical characteristics of the patients.

designRetrospective cohort.

settingSingle-center, University of Health Sciences, Ümraniye Training and Research Hospital. MATERIALS AND

methodsThis study was conducted between June 2023 and December 2024. Isolates were identified using VITEK MS v.3.2, and antibiotic susceptibility testing was performed using the VITEK 2 Compact system. CAZ-AVI susceptibility was determined using disk diffusion, and colistin susceptibility was determined using broth microdilution to determine minimum inhibitory concentration (MIC) values. Carbapenem resistance genes were determined using multiplex real-time polymerase chain reaction (RT-PCR) and clonal relationship arbitrarily primed-polymerase chain reaction (AP-PCR).

main outcome measuresResistance genes of CR-Kp isolates, clonal relationships, CAZ-AVI and colistin resistance, and clinical characteristics of patients. SAMPLE SIZE: Ninety-seven isolates from 76 patients.

resultsAmong patients with CR-Kp isolates, central venous catheter use was detected in 59 cases (78%), ventilator-associated pneumonia in 44 cases (58%), and bacteremia in 39 cases (51%), respectively. It was determined that 53 of the patients (70%) died. Using the AP-PCR method, 60 different genotypes were identified among 97 isolates, and clustering was determined in 42 of the isolates (46%). It was determined that 36 (37%) of the isolates were resistant to colistin and 42 (45%) were resistant to CAZ-AVI. NDM+OXA-48, OXA-48, KPC, KPC+NDM, and NDM genes were detected in 40 (43%), 32 (35%), 10 (11%), 2 (2%), and 3 (3%) isolates, respectively. It was determined that 30 (75%) of the isolates with NDM+OXA-48 and only 4 (12%) of the isolates with OXA-48 were resistant to CAZ-AVI.

conclusionIn addition to OXA-48, an increase in the frequency of CR-Kp isolates containing the NDM, NDM+OXA-48, KPC+NDM, and OXA-48+KPC genes were also detected. It was also determined that resistance to colistin and CAZ-AVI is increasing. The AP-PCR method can also be used to investigate infections. LIMITATIONS: Single center, Pulsed Field Gel Electrophoresis (PFGE) could not be performed together with AP-PCR.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeColistinKlebsiella InfectionsKlebsiella pneumoniaeAdultAgedCarbapenemsDrug CombinationsDrug Resistance, Multiple, BacterialFemaleHumansIntensive Care UnitsMaleMicrobial Sensitivity TestsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCarbapenemsCeftazidimeColistinDrug Combinationscarbapenemase genesCAZ-AVIclonal relationshipcolistinCR-Kp

Identifiers

PMID41562169
PMCPMC12820766

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.